Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02922946 · ClinicalTrials.gov registry record · Phase 1
Study to Determine the Effect of the Timing of a Meal on the Pharmacokinetics of Entinostat
A Phase 1 study, sponsored by Syndax Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT02922946 is a Phase 1 study that has completed, run by Syndax Pharmaceuticals. The registered enrollment target is 47 participants.
The verdict
NCT02922946, a Phase 1 study, has completed, sponsored by Syndax Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
The objectives of this study are to evaluate the effect of the timing of a moderate-fat meal on the single dose pharmacokinetics of entinostat and to evaluate the safety and tolerability of entinostat under fed and fasting conditions in healthy adult subjects.
Interventions
- DRUG Entinostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2016-10-11 |
| Est. Completion | 2017-06-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02922946
The ClinicalTrials.gov registry entry for NCT02922946 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Syndax Pharmaceuticals, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Entinostat is the first listed.
NCT02922946 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02922946 about?
NCT02922946 is a clinical study titled "Study to Determine the Effect of the Timing of a Meal on the Pharmacokinetics of Entinostat". The objectives of this study are to evaluate the effect of the timing of a moderate-fat meal on the single dose pharmacokinetics of entinostat and to evaluate the safety and tolerability of entinostat under fed and fasting conditions in healthy adult subjects.
What is the current status of trial NCT02922946?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2016-10-11. Estimated completion is 2017-06-26.
What interventions are being tested in trial NCT02922946?
The interventions under investigation include: Entinostat (DRUG).
Who is sponsoring clinical trial NCT02922946?
This trial is sponsored by Syndax Pharmaceuticals, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.